ALLOGENE THERAPEUTICS INC's ticker is ALLO and the CUSIP is 019770106. A total of 169 filers reported holding ALLOGENE THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 1.93 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $678,836 | +586.3% | 214,144 | +975.9% | 0.01% | +400.0% |
| Q2 2023 | $98,918 | -95.8% | 19,903 | -95.8% | 0.00% | -92.9% |
| Q1 2023 | $2,334,851 | +28.4% | 472,642 | +63.5% | 0.01% | +27.3% |
| Q4 2022 | $1,817,804 | -70.9% | 288,999 | -50.1% | 0.01% | -68.6% |
| Q3 2022 | $6,256,000 | +99.7% | 579,245 | +110.8% | 0.04% | +84.2% |
| Q2 2022 | $3,133,000 | +66.9% | 274,800 | +33.4% | 0.02% | +18.8% |
| Q1 2022 | $1,877,000 | -10.7% | 206,033 | +46.3% | 0.02% | -20.0% |
| Q4 2021 | $2,101,000 | -35.4% | 140,790 | +13.0% | 0.02% | -45.9% |
| Q2 2021 | $3,250,000 | +227.6% | 124,598 | +343.4% | 0.04% | +184.6% |
| Q1 2021 | $992,000 | -65.0% | 28,101 | -75.0% | 0.01% | -66.7% |
| Q4 2020 | $2,835,000 | +454.8% | 112,321 | +840.5% | 0.04% | +333.3% |
| Q2 2020 | $511,000 | +87.9% | 11,943 | -14.8% | 0.01% | +28.6% |
| Q1 2020 | $272,000 | -73.0% | 14,012 | -63.9% | 0.01% | -61.1% |
| Q4 2019 | $1,009,000 | – | 38,833 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VV Manager LLC | 1,798,163 | $76,997,000 | 67.53% |
| Wildcat Capital Management, LLC | 1,515,524 | $64,895,000 | 22.42% |
| TPG Group Holdings (SBS) Advisors, Inc. | 19,716,306 | $844,252,000 | 14.91% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 1,279,281 | $54,779,000 | 7.69% |
| Coastal Bridge Advisors, LLC | 463,117 | $19,831,000 | 6.33% |
| DSAM Partners (London) Ltd | 235,098 | $10,067,000 | 2.63% |
| Casdin Capital, LLC | 625,000 | $26,763,000 | 1.58% |
| Alpine Global Management, LLC | 150,000 | $6,423,000 | 1.13% |
| Perceptive Advisors | 1,543,790 | $66,105,000 | 1.07% |
| Avoro Capital Advisors LLC | 1,128,594 | $48,326,000 | 0.96% |